Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof

US10226525B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• Annaliesa Sybil Anderson · Upper Saddle River, US
• Amardeep Singh Bhupender Bhalla · Montvale, US
• Robert G. K. Donald · South Orange, US
• Jianxin Gu · River Edge, US
• Kathrin Ute Jansen · Doylestown, US
• Rajesh Kumar Kainthan · Tappan, US
• Lakshmi Khandke · Nanuet, US
• Jin-Hwan Kim · Suffern, US
• Paul Liberator · Holmdel, US
• Avvari Krishna Prasad · Chapel Hill, US
• Mark Edward Ruppen · Garnerville, US
• Ingrid Lea Scully · Patterson, US
• Suddham Singh · Monroe, US
• Cindy Xudong Yang · Tappan, US

Key dates

• Filing date: May 3, 2016
• Grant date: Mar 12, 2019
• Expiry date: May 7, 2036

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.